Embecta Dividends and Buybacks
Dividend criteria checks 4/6
Embecta is a dividend paying company with a current yield of 15.38% that is well covered by earnings.
Key information
15.4%
Dividend yield
1.2%
Buyback Yield
| Total Shareholder Yield | 16.6% |
| Future Dividend Yield | 15.4% |
| Dividend Growth | 17.2% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 25% |
Recent dividend and buyback updates
Recent updates
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Embecta: An Interesting Deal At An Interesting Time
Mar 19
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
Feb 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 09Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Feb 08EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
Jan 09EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
Nov 28Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Nov 01Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 26Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Aug 28GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Jul 04Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
May 22What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
May 09Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Mar 06Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Feb 28New Initiatives Expected To Make Embecta More Profitable
Dec 04Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Nov 29At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
Nov 07It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Sep 24
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Aug 16Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Aug 14When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
Jul 13Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 12Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
Feb 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, EMBC has been paying a dividend for less than 10 years.
Growing Dividend: EMBC has only been paying a dividend for 4 years, and since then payments have not increased.
Dividend Yield vs Market
| Embecta Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EMBC) | 15.4% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Medical Equipment) | 2.2% |
| Analyst forecast (EMBC) (up to 3 years) | 15.4% |
Notable Dividend: EMBC's dividend (15.38%) is higher than the bottom 25% of dividend payers in the US market (1.42%).
High Dividend: EMBC's dividend (15.38%) is in the top 25% of dividend payers in the US market (4.3%)
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (25.2%), EMBC's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (17.3%), EMBC's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 11:15 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Embecta Corp. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |